If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Subjects receiving DTG","arm_group_description":"HIV-1 subjects in whom a treatment with DTG has been initiated outside clinical trial/compassionate use or medical need program setting during the period between 01 October 2014 and 01 December 2017 and who have taken >=1 dose of DTG will be included in the analysis.","arm_type":""}],"assignment":"","brief_summary":"The aim of this analysis is to generate data on the use of DTG in daily clinical practice in Belgium in a cohort of HIV-infected adult subjects. This is a non-interventional, non-comparative, retrospective, observational multicenter cohort study. Data from all HIV-1 subjects who initiated treatment with DTG outside clinical trial/compassionate use or medical need program setting during the period between 01 October 2014 and 01 December 2017 and who have taken >=1 dose of DTG will be included in the analysis. Anonymized data will be extracted and collected from existing databases in selected Belgian acquired immunodeficiency syndrome (AIDS) centers and pooled into one common database.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Belgian multicentre non-interventional, observational, retrospective study of daily practice use of dolutegravir in the treatment of HIV positive patients","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"05/20/2020 14:09:36","criteria":"Inclusion Criteria:\n - >= 18 years of age.\n - Male or female.\n - HIV-1 positive.\n - DTG treatment initiated in the period between 01 October 2014 and 01 December 2017, and receiving >= 1 dose of DTG in this defined time period.\n\nExclusion Criteria:\n - Subjects who have been participating in a clinical trial or a compassionate use / medical need program with DTG.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"N/A","display_phase_internal":"PHASE_NA","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"1000","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"","id":"7123b6e7-c2b6-565d-9b3b-8f6a4ba29250","internal":{"content":null,"contentDigest":"518c824ed0635ed23c1e507a15a18b59","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria:\n - >= 18 years of age.\n - Male or female.\n - HIV-1 positive.\n - DTG treatment initiated in the period between 01 October 2014 and 01 December 2017, and receiving >= 1 dose of DTG in this defined time period.\n\nExclusion Criteria:\n - Subjects who have been participating in a clinical trial or a compassionate use / medical need program with DTG.","interventions":[],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["Dolutegravir","HIV","Highly active antiretroviral therapy","Belgium","Antiretroviral"],"last_follow_up_date":"10/31/2018 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"05/20/2020 14:09:36","number_of_arms":"0","observational_design":{"biospecimen_description":"","biospecimen_retention":"None Retained","number_of_groups":"1","observational_study_design":"Cohort","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"A Belgian multicentre non-interventional, observational, retrospective study of daily practice use of dolutegravir in the treatment of HIV positive patients","org_study_id":"209457","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"N/A","primary_compl_date":"10/31/2018 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Number of subjects with virologic suppression","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null}],"product_name":"abacavir;dolutegravir;dolutegravir/abacavir/lamivudine;lamivudine","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Number of subjects with virologic rebound","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with virologic non-response","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with low level viremia (partial suppression)","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of subjects with HIV-RNA < 400 copies/milliliter","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Reason for change in concomitant backbone therapy","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to change in concomitant backbone therapy","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"DTG discontinuation rate","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Reason for discontinuation of DTG","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to virological failure","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Change from Baseline in cluster of differentiation 4 (CD4) count","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with emergence of resistance to DTG","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects with emergence of resistance to other antiretrovirals (ARV’s)","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Change from Baseline in cardiovascular (CV)-lipid parameters","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Change from Baseline in body mass index (BMI)","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Number of subjects who switched from DTG therapy","outcome_time_frame":"Weeks 24, 48 and 96","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["BREACH (Belgium Research on AIDS and HIV Consortium)"]},"start_date":"09/21/2018 00:00:00","study_type":"Observational","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"209457"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}